Asset
Persicabtagene Lemgedleucel
Sana Biotechnology Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (2)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06294236 | phase1 | active_not_recruiting | 2024-04-29 | 2027-12-01 | Sana Biotechnology | Study Evaluating SC291 in Subjects With Severe r/r B-cell Mediated Autoimmune Diseases (GLEAM) |
| NCT05878184 | phase1 | active_not_recruiting | 2023-05-02 | 2025-11-04 | Sana Biotechnology | Study Evaluating SC291 in Subjects With r/r B-cell Malignancies (ARDENT) |
FDA applications (0)
This company has no applications containing this asset.